Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04918186 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT04918186 is a Phase 2 study of Ovarian Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 60 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT04918186, a Phase 2 study of Ovarian Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Conditions Studied
Interventions
- DRUG Toripalimab
- DRUG Durvalumab
- DRUG BA3011
- DRUG BA3021
- DRUG ENB003
Study Locations (7)
British Columbia
- BCCA - Kelowna - Kelowna
- BCCA - Vancouver - Vancouver
Ontario
- Odette Cancer Centre - Toronto
- University Health Network - Toronto
Quebec
- CHUM-Centre Hospitalier de l'Universite de Montreal - Montreal
- The Jewish General Hospital - Montreal
Illinois
- The University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04918186
The ClinicalTrials.gov registry entry for NCT04918186 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Toripalimab is the first listed.
NCT04918186 reports 7 study locations spanning 4 distinct geographic areas - top geographies include British Columbia, Ontario, Quebec.
Frequently Asked Questions
What is clinical trial NCT04918186 about?
NCT04918186 is a clinical study titled "Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer". This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
What is the current status of trial NCT04918186?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-05-03. Estimated completion is 2026-12-31.
What conditions does trial NCT04918186 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT04918186?
The interventions under investigation include: Toripalimab (DRUG), Durvalumab (DRUG), BA3011 (DRUG), BA3021 (DRUG), ENB003 (DRUG).
Who is sponsoring clinical trial NCT04918186?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04918186 being conducted?
This trial has 7 study locations across Illinois, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.